LigaChemBio to Host 'Global R&D DAY 2025' on July 1...Unveiling Next-Generation ADC Pipeline and Growth Strategy

- Presentation of global clinical status of core pipeline Caxmotabart Entudotin (HER2-ADC) and CS5001 (ROR1-ADC)

- Disclosure of next-generation ADC pipeline and expansion strategy into immuno-oncology field

- Presentation of global technology transfer strategy and key growth driver roadmap

LigaChemBio Biosciences Co., Ltd. (141080KS, hereinafter 'LigaChemBio') announced that it will host 'LigaChemBio Global R&D DAY 2025' in Seoul, Yeouido on July 1st. The event will run from 9:30 AM to 3:50 PM, serving as a platform to share LigaChemBio's research and development status and mid-to-long-term strategies with key stakeholders including investors, analysts, and media, while showcasing the company's globally leading ADC (Antibody-Drug Conjugate) technology capabilities and business vision. The event will also be broadcast live on YouTube in both Korean and English for domestic and international investors and ADC experts.

The event consists of three parts designed to comprehensively introduce the company's technological capabilities and business strategies. The first part will feature presentations on the expansion potential of ADC technology and how LigaChemBio's platform technology differentiates itself in clinical strategy. Additionally, the global clinical status and practical application cases of major pipelines including HER2-ADC and ROR1-ADC, interim results from Phase 1 clinical trials, and future development strategies will be disclosed.

The second part focuses on next-generation ADC technology and innovation in the immuno-oncology field. Various innovative candidate substances currently under development will be introduced, along with the differentiation of recently licensed targets and technology expansion strategies into the immuno-oncology field.

The final part will present LigaChemBio's global business strategy and growth vision. Technology transfer strategies for expanding overseas partnerships will be discussed, along with specific presentations of mid-to-long-term business roadmaps and key growth drivers through 2030. In-depth discussions through Q&A sessions with attendees will follow each presentation.

LigaChemBio is focusing on next-generation ADC development based on its proprietary ConjuALL platform technology, with multiple pipelines having entered clinical stages. Key candidate substances such as HER2-ADC and ROR1-ADC are particularly gaining attention in global clinical trials. Through this Global R&D Day, LigaChemBio plans to comprehensively present its differentiated competitive advantages in ADC technology, expansion into immuno-oncology fields, and global partnership expansion strategies, while concretizing its vision as a leading company in next-generation anticancer drug development.

Event Overview

• Event Name: LigaChemBio Global R&D DAY 2025
• Date & Time: Tuesday, July 1, 2025, 9:30 AM ~ 3:50 PM
• Theme: LigaChemBio R&D Status and Mid-to-Long-term Strategy
• YouTube Link(English version): https://www.youtube.com/live/QyOZInp_jRI?si=NQRDFI7qw5HhrP4Q

End.